201 Route 17 North, 2nd Floor / Meadows Office Complex
NJ 07070 Rutherford, us
Cancer Genetics, Inc. Selected By Gilead Sciences, Inc. to Provide Clinical Trial Services for International Trials in Chronic Lymphocytic Leukemia
Comprehensive, biomarker-based patient profiling will help risk stratification, improve trial efficacy and provide biomarker driven insight regarding patient targeting and potential outcomes
Targeted therapies have the potential of improving the lives of cancer patients and providing them with better treatment outcome. CGI's SelectOne(TM) offering empowers biotech and pharma companies like Gilead to achieve their goals in oncology clinical trials through the use of CGI's comprehensive oncology focused menu and proprietary microarrays.
CGI expects the trials to continue for the next several years, and may potentially enable an expedited and more efficient development timeline based on improved patient stratification. CGI also offers comprehensive CLL testing to cancer centers, oncologists and community hospitals under its CLL CompleteSM offering. This includes the assessment of ZAP-70, CD38, mutational status of IGHV, TP53 and SF3B1, genomic alterations by FISH and by a proprietary genomic microarray - MatBA®-CLL/SLL which includes a comprehensive report stratifying the risk and potential outcome, to guide disease and patient management. CLL is a clinically heterogeneous disease and the most common form of leukemia in the Western Hemisphere. It is estimated that in the United States there is a new case diagnosed every forty minutes and there are over 110,000 people living with CLL.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an firstname.lastname@example.org.